PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)

被引:0
|
作者
Wen, Patrick [1 ]
Kuhn, John [2 ]
Chang, Susan [3 ]
Lamborn, Kathleen [3 ]
Robbins, Hi [4 ]
Cloughesy, Timothy [5 ]
Lieberman, Frank [6 ]
Mehra, Minesh [7 ]
Gilbert, Mark
Cooper, Josh
Drappatz, Jan [8 ]
Kesari, Santosh
Norden, Andrew
Groves, Morris [9 ]
Aldape, Kenneth [9 ]
Yung, W. K. Alfred [9 ]
Dancey, Janet [10 ]
Prados, Michael [3 ]
机构
[1] Ctr Neurooncol, Boston, MA USA
[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Univ Wisconsin, Madison, WI USA
[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] NCI, Bethesda, MD 20892 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:824 / 824
页数:1
相关论文
共 50 条
  • [31] A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: AChildren's Oncology Group Phase I Consortium Report
    Fouladi, Maryam
    Perentesis, John P.
    Wagner, Lars M.
    Vinks, Alexander A.
    Reid, Joel M.
    Ahern, Charlotte
    Thomas, George
    Mercer, Carol A.
    Krueger, Darcy A.
    Houghton, Peter J.
    Doyle, L. Austin
    Chen, Helen
    Weigel, Brenda
    Blaney, Susan M.
    CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1558 - 1565
  • [32] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
  • [33] FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OF TEMSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GLIOBLASTOMA: NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572
    Schiff, David
    Sarkaria, Jann
    Decker, Paul
    Buckner, Jan
    Galanis, Evanthia
    Dancey, Janet
    Giannini, Caterina
    Brown, Paul
    Wiesenfeld, Martin
    Jaeckle, Kurt
    NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
  • [34] Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas
    Sathornsumetee, S.
    Desjardins, A.
    Vredenburgh, J. J.
    Rich, J. N.
    Gururangan, S.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08)
    Wen, PY
    Yung, WKA
    Lamborn, K
    Peng, B
    Dahia, P
    Abrey, L
    Raiser, J
    Cloughesy, T
    Fink, K
    Gilbert, M
    Chang, S
    Junck, L
    Schiff, D
    Lieberman, F
    Fine, H
    Mehta, M
    Robins, HI
    DeAngelis, LM
    Hess, K
    Groves, M
    Puduvalli, VK
    Levin, V
    Conrad, C
    Kuhn, J
    Maher, E
    Hayes, M
    Silberman, S
    Letvak, L
    Capdeville, R
    Kaplan, R
    Murgo, A
    Stiles, C
    Prados, MD
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
  • [36] A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas A Study of the Mayo Phase 2 Consortium (P2C)
    Okuno, Scott
    Bailey, Howard
    Mahoney, Michelle R.
    Adkins, Douglas
    Maples, William
    Fitch, Tom
    Ettinger, David
    Erlichman, Charles
    Sarkaria, Jann N.
    CANCER, 2011, 117 (15) : 3468 - 3475
  • [37] Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Rourke, Meghan
    Schlossman, Robert L.
    Laubach, Jacob P.
    Jakubowiak, Andrzej J.
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott J.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2010, 116 (21) : 435 - 436
  • [38] Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
    Sarantopoulos, J.
    Lenz, H.
    LoRusso, P.
    Shibata, S.
    Kummar, S.
    Mulkerin, D.
    Ramanathan, R. K.
    Mita, M. M.
    O'Rourke, P.
    Remick, S. C.
    Goel, S.
    Gutierrez, M.
    Ramalingam, S. S.
    Murgo, A.
    Davies, A. M.
    Mani, S.
    Boni, J.
    Shapiro, M.
    Ivy, S. P.
    Takimoto, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor.
    Hidalgo, M
    Rowinsky, E
    Erlichman, C
    Drengler, R
    Marshall, B
    Marks, R
    Edwards, T
    Boni, J
    Dukart, G
    Buckner, J
    ANNALS OF ONCOLOGY, 2000, 11 : 133 - 133
  • [40] Phase I/II study of vandetanib for patients with recurrent malignant gliomas.
    Mcnicol, K. A.
    Kreisl, T. N.
    Iwamoto, F. M.
    Sul, J.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)